Over a fourth of BSE500 companies have fallen more than 30% in the past year and half of the index constituents are down over 30% from their 2-year highs

Demand for branded personal care products from high-income consumers has held up. With prices of certain commodities softening, profits for fast-moving consumer goods companies are expected to improve, according to analysts.

Mutual fund body AMFI is likely to announce the official list of the semi-annual review for the second half of 2022. Prior to this, various brokerage firms and analysts have launched their initial expectations for the same.

The U.S. selections included none of the nine stadiums used at the 1994 World Cup. The Rose Bowl in Pasadena, California, and Orlando's Camping World Stadium were the only ones remaining in contention, and they were among the sites dropped in the final round.

HDFC, Adani Wilmar, Britannia, Tata Consumer, IDBI Bank, CG Power, M&M Financial, Devyani International, Alembic Pharma, Castrol India, JSPL and Saregama India are among the companies that will announce their March quarter results today.

Wipro, Maruti Suzuki, Ultratech, SBI Cards, IndusInd Bank, Star Health, Supreme Industries, Tata Chemicals, Tanla Platforms, HFCL, Gillette and Sonata Software are among the companies that will announce their March quarter results today.

Braun, a subsidiary of Procter & Gamble was founded in Germany in 1921 and was acquired by Gillette in 1967. Gillette said the addition of Braun adds an extensive range of both male and female grooming products like electric shavers, trimmers, epilators, hair removal devices, and hair care devices to the companys existing portfolio.

Its net sales were 11.02 per cent to Rs 573.31 crore during the quarter under review against Rs 516.40 crore a year ago, Gillette India said in a BSE filing.

Bharti Airtel, Sun Pharma, Dabur, Godrej Properties, Hindustan Petroleum, Jindal Steel, Trent, Union Bank of India, Bank of India and Radico Khaitan are among the companies that will announce their September quarter results today.

P&G is the world's largest consumer-goods maker and dominates many of its businesses. For example, analysts estimate its Bounty brand accounts for 40% of all paper towels sold in the United States.

Chart is self explanatory. Entry, Targets and Stop Loss are mentioned on the chart. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.

Data compiled from corporate database AceEquity suggests one-third of 98 BSE Midcap constituents need to rally at least 50 per cent to reclaim their record high levels.

Manish Hathiramani, technical analyst at Deen Dayal Investments said, "If the Nifty50 is able to get past the 14,950 level on a closing basis, then it could move higher to 15,300-15,400."

The sector was in focus in Union Budget 2021. Finance Minister Nirmala Sitharaman in her Budget speech announced an outlay of Rs 2,23,846 crore for health and well being.

ICICI Direct is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 460 in its research report dated January 29, 2021.

Motilal Oswal is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 460 in its research report dated January 28, 2021.

The approved product is bioequivalent to the reference listed drug Potassium Chloride Oral Solution of Genus Lifesciences, Inc.

Sharekhan is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 475 in its research report dated January 28, 2021.

The share touched its 52-week high Rs 438.00 and 52-week low Rs 114.50 on 01 December, 2020 and 23 March, 2020, respectively.

The approved product is the generic equivalent of Glumetza ER tablets, 500 mg and 1000 mg, of Bausch Health US LLC.

P&G said it delivered a resilient performance in the fiscal despite a challenging economic environment and pandemic-related disruption in March 2020.

Sharekhan is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 475 in its research report dated January 06, 2020.

Granules India announced that the US FDA has approved the ANDA filed by Granules Pharmaceuticals, Inc (GPI)., for Penicillamine Capsules USP, 250 mg, the company said in an exchange filing.

The company, however, did not share more details.

ICICI Direct is bullish on Granules India recommended buy rating on the stock with a target price of Rs 460 in its research report dated October 21, 2020.

KRChoksey is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 459 in its research report dated October 22, 2020.

Anand Rathi is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 455 in its research report dated October 22, 2020.

Sharekhan is bullish on Granules India Limited has recommended buy rating on the stock with a target price of Rs 475 in its research report dated October 20, 2020.

Motilal Oswal is bullish on Granules India recommended buy rating on the stock with a target price of Rs 500 in its research report dated October 20, 2020.